REPLY
20.11.2023 09:31:34 CET | Business Wire | Press release
Up Reply, the agency within the Reply Group specialised in digital growth and experience optimisation, today announced that it has been recognised by Dynamic Yield as a winner of the 2023 Personalization Awards. The company received the Partner Excellence Award for its holistic approach to digital transformation, including the design and implementation of personalisation programmes that enable clients to successfully achieve their business goals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120075128/en/
Up Reply receives the Partner Excellence Award in the 2023 Personalization Awards from Dynamic Yield. (Photo: Reply)
Up Reply was recognised for its expertise in digital growth and experience optimisation, leading the way with data-driven methods for personalising digital channels and delivering user-centric experiences that align with clients' business objectives.
The Dynamic Yield Personalization Awards celebrate the achievements of leading brands and solution partners who are going above and beyond when it comes to tailoring experiences. The winners represent pioneers at the forefront of customer experience and serve as a beacon for digital-first organisations investing in personalisation.
Anoop Vasisht, Chief Revenue Officer at Dynamic Yield by Mastercard commented: "Up Reply's exceptional expertise in personalisation and their dedication to helping clients achieve their business goals through user-centric experiences is truly commendable. Their commitment to digital growth and experience optimisation, combined with their tailored consulting and hands-on support, makes them a winner of the Partner Excellence Award 2023. Up Reply's partnership with Dynamic Yield exemplifies the spirit of innovation and excellence that our Personalization Awards celebrate. We look forward to their continued success and the impact they will continue to make in the world of personalisation."
Up Reply received the Partner Excellence Award for its approach to developing a personalised strategy for companies based on existing data and optimising their specific user journey. In particular, Up Reply supports its clients in the operational implementation of their personalisation, experimentation and optimisation programmes. This ongoing support covers various elements of the process chain, including user analysis, ideation, project management, concept development, technical implementation, evaluation and more.
In addition, Up Reply provides comprehensive consulting tailored to the specific needs of each business, with hands-on learning to ensure that clients can confidently navigate and use technologies such as Dynamic Yield's to gain valuable insights and facilitate decision making.
Filippo Rizzante, CTO at Reply said: "We are proud of how Up Reply is using personalisation to drive digital transformation and optimise the customer experience. This award from Dynamic Yield truly validates our success in these efforts, and we look forward to continuing to find ways to move the industry forward with innovative solutions."
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
Up Reply
Up Reply is the Reply Group company specialising in digital growth and experience optimisation. The experts provide international clients with data-driven methods for personalisation of digital channels, A/B testing, and analytics across the entire customer journey. The result is user-centered experiences that contribute to the business objectives. Up Reply supports with strategy consulting, onboarding and offers full service with tools such as Dynamic Yield, Optimizely, Adobe Target or Adobe Analytics, Google Analytics and Contentsquare. upreply.de/en/
Dynamic Yield by Mastercard
Dynamic Yield by Mastercard helps businesses across industries deliver digital customer experiences that are personalized, optimized, and synchronized. With Dynamic Yield’s Experience OS, marketers, product managers, developers, and digital teams can algorithmically match content, products, and offers to each individual customer for the acceleration of revenue and customer loyalty. More information on Dynamic Yield’s Personalization Awards: www.dynamicyield.com/personalization-awards/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231120075128/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom